Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges

被引：151

作者：

Dufour, Jean-Francois ^{[1
,2
]}

Caussy, Cyrielle ^{[3
,4
]}

Loomba, Rohit ^{[5
]}

机构：

[1] Univ Bern, Dept Clin Res, Hepatol, CH-3010 Bern, Switzerland

[2] Inselspital Bern, Univ Clin Visceral Surg & Med, Bern, Switzerland

[3] Univ Lyon 1, Hosp Civils Lyon, Ctr Hosp Lyon Sud Endocrinol Diabete & Nutr, Lyon, France

[4] Univ Calif San Diego, NAFLD Res Ctr, La Jolla, CA 92093 USA

[5] Univ Calif San Diego, NAFLD Res Ctr, Dept Med, Div Gastroenterol & Hepatol, La Jolla, CA 92093 USA

来源：

GUT | 2020年 / 69卷 / 10期

基金：

瑞士国家科学基金会;

关键词：

nonalcoholic steatohepatitis; hepatobiliary disease; liver; FATTY LIVER-DISEASE; TYPE-2; DIABETES-MELLITUS; CHRONIC KIDNEY-DISEASE; CARDIOVASCULAR OUTCOMES; INSULIN-RESISTANCE; ADVANCED FIBROSIS; HIGH PREVALENCE; OBESE-PATIENTS; PLACEBO; ASSOCIATION;

D O I：

10.1136/gutjnl-2019-319104

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Non-alcoholic steatohepatitis (NASH) is becoming a leading cause of cirrhosis with the burden of NASH-related complications projected to increase massively over the coming years. Several molecules with different mechanisms of action are currently in development to treat NASH, although reported efficacy to date has been limited. Given the complexity of the pathophysiology of NASH, it will take the engagement of several targets and pathways to improve the results of pharmacological intervention, which provides a rationale for combination therapies in the treatment of NASH. As the field is moving towards combination therapy, this article reviews the rationale for such combination therapies to treat NASH based on the current therapeutic landscape as well as the advantages and limitations of this approach.

引用

页码：1877 / 1884

页数：8

共 69 条

[1]

Amin N, 2019, HEPATOLOGY, V70, p21A

[2]

[Anonymous], NEW ENGL J MED

[3] High prevalence of undiagnosed liver cirrhosis and advanced fibrosis in type 2 diabetic patients [J].

Arab, Juan P. ;

Barrera, Francisco ;

Gallego, Consuelo ;

Valderas, Juan P. ;

Uribe, Sergio ;

Tejos, Cristian ;

Serrano, Cristbal ;

Huete, Alvaro ;

Liberona, Jessica ;

Labbe, Pilar ;

Quiroga, Teresa ;

Benitez, Carlos ;

Irarrazaval, Pablo ;

Riquelme, Arnoldo ;

Arrese, Marco .

ANNALS OF HEPATOLOGY, 2016, 15 (05) :721-728

[4] Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program [J].

Armstrong, M. J. ;

Houlihan, D. D. ;

Rowe, I. A. ;

Clausen, W. H. O. ;

Elbrond, B. ;

Gough, S. C. L. ;

Tomlinson, J. W. ;

Newsome, P. N. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2013, 37 (02) :234-242

[5] Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study [J].

Armstrong, Matthew James ;

Gaunt, Piers ;

Aithal, Guruprasad P. ;

Barton, Darren ;

Hull, Diana ;

Parker, Richard ;

Hazlehurst, Jonathan M. ;

Guo, Kathy ;

Abouda, George ;

Aldersley, Mark A. ;

Stocken, Deborah ;

Gough, Stephen C. ;

Tomlinson, Jeremy W. ;

Brown, Rachel M. ;

Huebscher, Stefan G. ;

Newsome, Philip N. .

LANCET, 2016, 387 (10019) :679-690

[6] Nonalcoholic Fatty Liver Disease, Hepatic Insulin Resistance, and Type 2 Diabetes [J].

Birkenfeld, Andreas L. ;

Shulman, Gerald I. .

HEPATOLOGY, 2014, 59 (02) :713-723

[7] Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial [J].

Bril, Fernando ;

Biernacki, Diane M. ;

Kalavalapalli, Srilaxmi ;

Lomonaco, Romina ;

Subbarayan, Sreevidya K. ;

Lai, Jinping ;

Tio, Fermin ;

Suman, Amitabh ;

Orsak, Beverly K. ;

Hecht, Joan ;

Cusi, Kenneth .

DIABETES CARE, 2019, 42 (08) :1481-1488

[8] Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD [J].

Bril, Fernando ;

Sninsky, John J. ;

Baca, Arthur M. ;

Superko, H. Robert ;

Sanchez, Paola Portillo ;

Biernacki, Diane ;

Maximos, Maryann ;

Lomonaco, Romina ;

Orsak, Beverly ;

Suman, Amitabh ;

Weber, Michelle H. ;

McPhaul, Michael J. ;

Cusi, Kenneth .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2016, 101 (02) :644-652

[9] Metabolic disturbances in non-alcoholic fatty liver disease [J].

Byrne, Christopher D. ;

Olufadi, Rasaq ;

Bruce, Kimberley D. ;

Cagampang, Felino R. ;

Ahmed, Mohamed H. .

CLINICAL SCIENCE, 2009, 116 (7-8) :539-564

[10] Ketohexokinase inhibitor PF-06835919 administered for 6 weeks reduces whole liver fat as measured by magnetic resonance imaging-proton density fat fraction in subjects with non-alcoholic fatty liver disease [J].

Calle, Roberto ;

Bergman, Arthur ;

Somayaji, Veena ;

Chidsey, Kristin ;

Kazierad, David .

JOURNAL OF HEPATOLOGY, 2019, 70 (01) :E69-E70

← 1 2 3 4 5 6 7 →